134 related articles for article (PubMed ID: 37952139)
61. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
[TBL] [Abstract][Full Text] [Related]
62. Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation.
Nagler A; Labopin M; Dholaria B; Wu D; Choi G; Aljurf M; Ciceri F; Gedde-Dahl T; Meijer E; Niittyvuopio R; Bondarenko S; Bourhis JH; Cornelissen JJ; Socié G; Koc Y; Canaani J; Savani B; Bug G; Spyridonidis A; Giebel S; Brissot E; Bazarbachi A; Esteve J; Mohty M
Transplant Cell Ther; 2022 Feb; 28(2):86.e1-86.e8. PubMed ID: 34856420
[TBL] [Abstract][Full Text] [Related]
63. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation.
Mehta RS; Saliba RM; Rondon G; Al-Atrash G; Bashir Q; Hosing CM; Kebriaei P; Khouri I; Nieto Y; Oran B; Popat UR; Qazilbash MH; Ramdial J; Srour SA; Champlin RE; Rezvani K; Shpall EJ; Alousi AM
Transplant Cell Ther; 2022 Oct; 28(10):695.e1-695.e10. PubMed ID: 35902049
[TBL] [Abstract][Full Text] [Related]
64. Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
Mohty R; Al Kadhimi Z; Kharfan-Dabaja M
Hematology; 2024 Dec; 29(1):2326384. PubMed ID: 38597828
[TBL] [Abstract][Full Text] [Related]
65. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Sanz J; Galimard JE; Labopin M; Afanasyev B; Angelucci E; Ciceri F; Blaise D; Cornelissen JJ; Meijer E; Diez-Martin JL; Koc Y; Rovira M; Castagna L; Savani B; Ruggeri A; Nagler A; Mohty M;
J Hematol Oncol; 2020 May; 13(1):46. PubMed ID: 32375860
[TBL] [Abstract][Full Text] [Related]
66. Bacterial Bloodstream Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide.
Salas MQ; Charry P; Puerta-Alcalde P; Martínez-Cibrian N; Solano MT; Serrahima A; Nomdedeu M; Cid J; Lozano M; Chumbinta M; Aiello TF; Arcarons J; LLobet N; Pedraza A; Rosiñol L; Esteve J; Urbano-Ispizua Á; Carreras E; Martínez C; Fernández-Avilés F; García-Vidal C; Suárez-Lledó M; Rovira M
Transplant Cell Ther; 2022 Dec; 28(12):850.e1-850.e10. PubMed ID: 36089250
[TBL] [Abstract][Full Text] [Related]
67. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB
Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792
[TBL] [Abstract][Full Text] [Related]
68. [Current state of graft-versus-host disease prophylaxis with PTCy for allogeneic hematopoietic stem cell transplantation].
Nakamae H
Rinsho Ketsueki; 2024; 65(5):391-400. PubMed ID: 38825519
[TBL] [Abstract][Full Text] [Related]
69. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
Saliba RM; Alousi AM; Pidala J; Arora M; Spellman SR; Hemmer MT; Wang T; Abboud C; Ahmed S; Antin JH; Beitinjaneh A; Buchbinder D; Byrne M; Cahn JY; Choe H; Hanna R; Hematti P; Kamble RT; Kitko CL; Laughlin M; Lekakis L; MacMillan ML; Martino R; Mehta PA; Nishihori T; Patel SS; Perales MA; Rangarajan HG; Ringdén O; Rosenthal J; Savani BN; Schultz KR; Seo S; Teshima T; van der Poel M; Verdonck LF; Weisdorf D; Wirk B; Yared JA; Schriber J; Champlin RE; Ciurea SO
Transplant Cell Ther; 2022 Oct; 28(10):681-693. PubMed ID: 35853610
[TBL] [Abstract][Full Text] [Related]
70. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
[TBL] [Abstract][Full Text] [Related]
71. Plasma from patients undergoing allogeneic hematopoietic stem cell transplantation promotes NETOSIS
López-Andrade B; Cunill V; Andreu V; Bento L; Segura-Guerrero M; Moñino A; Iglesias J; Julià MR; Durán MA; Ballester MC; Muncunill J; Sampol A
Front Immunol; 2024; 15():1353106. PubMed ID: 38550584
[TBL] [Abstract][Full Text] [Related]
72. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
Sanz J; Galimard JE; Labopin M; Afanasyev B; Sergeevich MI; Angelucci E; Kröger N; Koc Y; Ciceri F; Diez-Martin JL; Arat M; Sica S; Rovira M; Aljurf M; Tischer J; Savani B; Ruggeri A; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):84. PubMed ID: 34049582
[TBL] [Abstract][Full Text] [Related]
73. Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation.
Peña M; Salas MQ; Mussetti A; Moreno-Gonzalez G; Bosch A; Patiño B; Jiménez L; Kara M; Parody R; Sureda A
Blood Adv; 2021 Sep; 5(17):3418-3426. PubMed ID: 34495311
[TBL] [Abstract][Full Text] [Related]
74. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
[TBL] [Abstract][Full Text] [Related]
75. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
76. Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis.
Cioccio J; Rakszawski K; Zheng H; Nickolich M; Naik S; Wirk B; Rybka W; Ehmann C; Silar B; Vajdic C; Shah N; Tuanquin L; Greiner R; Brown V; Hohl R; Claxton D; Mineishi S; Minagawa K; Shike H
Ann Hematol; 2023 Mar; 102(3):613-620. PubMed ID: 36527460
[TBL] [Abstract][Full Text] [Related]
77. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation.
Penack O; Abouqateb M; Peczynski C; Boreland W; Gülbas Z; Gedde-Dahl T; Castilla-Llorente C; Kröger N; Eder M; Rambaldi A; Bonifazi F; Blau IW; Stelljes M; Dreger P; Moiseev I; Schoemans H; Koenecke C; Peric Z
Blood Cancer J; 2024 Mar; 14(1):45. PubMed ID: 38485723
[TBL] [Abstract][Full Text] [Related]
78. Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors.
George B; Pn N; Devasia AJ; Kulkarni U; Korula A; Lakshmi KM; Abraham A; Srivastava A; Mathews V
Biol Blood Marrow Transplant; 2018 Mar; 24(3):494-500. PubMed ID: 29100905
[TBL] [Abstract][Full Text] [Related]
79. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Brissot E; Labopin M; Labussière H; Fossard G; Chevallier P; Guillaume T; Yakoub-Agha I; Srour M; Bulabois CE; Huynh A; Chantepie S; Menard AL; Rubio MT; Ceballos P; Dulery R; Furst S; Malard F; Blaise D; Mohty M
Blood Cancer J; 2024 Feb; 14(1):31. PubMed ID: 38374026
[TBL] [Abstract][Full Text] [Related]
80. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
